<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2022-03-11T00:49:56Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8412346" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8412346</identifier>
        <datestamp>2021-09-03</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS One</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8412346</article-id>
              <article-id pub-id-type="pmcid">PMC8412346</article-id>
              <article-id pub-id-type="pmc-uid">8412346</article-id>
              <article-id pub-id-type="pmid">34473809</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0257107</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-21-12208</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>People and Places</subject>
                  <subj-group>
                    <subject>Population Groupings</subject>
                    <subj-group>
                      <subject>Age Groups</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Vaccination and Immunization</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Vaccination and Immunization</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Public and Occupational Health</subject>
                    <subj-group>
                      <subject>Preventive Medicine</subject>
                      <subj-group>
                        <subject>Vaccination and Immunization</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Infectious Diseases</subject>
                      <subj-group>
                        <subject>Infectious Disease Control</subject>
                        <subj-group>
                          <subject>Vaccines</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Social Sciences</subject>
                  <subj-group>
                    <subject>Economics</subject>
                    <subj-group>
                      <subject>Health Economics</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Health Care</subject>
                    <subj-group>
                      <subject>Health Economics</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>People and Places</subject>
                  <subj-group>
                    <subject>Geographical Locations</subject>
                    <subj-group>
                      <subject>Asia</subject>
                      <subj-group>
                        <subject>Japan</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Infectious Diseases</subject>
                      <subj-group>
                        <subject>Viral Diseases</subject>
                        <subj-group>
                          <subject>Covid 19</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Epidemiology</subject>
                    <subj-group>
                      <subject>Infectious Disease Epidemiology</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Infectious Diseases</subject>
                      <subj-group>
                        <subject>Infectious Disease Epidemiology</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and life sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Viruses</subject>
                      <subj-group>
                        <subject>RNA viruses</subject>
                        <subj-group>
                          <subject>Coronaviruses</subject>
                          <subj-group>
                            <subject>SARS coronavirus</subject>
                            <subj-group>
                              <subject>SARS CoV 2</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and life sciences</subject>
                  <subj-group>
                    <subject>Microbiology</subject>
                    <subj-group>
                      <subject>Medical microbiology</subject>
                      <subj-group>
                        <subject>Microbial pathogens</subject>
                        <subj-group>
                          <subject>Viral pathogens</subject>
                          <subj-group>
                            <subject>Coronaviruses</subject>
                            <subj-group>
                              <subject>SARS coronavirus</subject>
                              <subj-group>
                                <subject>SARS CoV 2</subject>
                              </subj-group>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and health sciences</subject>
                  <subj-group>
                    <subject>Pathology and laboratory medicine</subject>
                    <subj-group>
                      <subject>Pathogens</subject>
                      <subj-group>
                        <subject>Microbial pathogens</subject>
                        <subj-group>
                          <subject>Viral pathogens</subject>
                          <subj-group>
                            <subject>Coronaviruses</subject>
                            <subj-group>
                              <subject>SARS coronavirus</subject>
                              <subj-group>
                                <subject>SARS CoV 2</subject>
                              </subj-group>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and life sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Viruses</subject>
                      <subj-group>
                        <subject>Viral pathogens</subject>
                        <subj-group>
                          <subject>Coronaviruses</subject>
                          <subj-group>
                            <subject>SARS coronavirus</subject>
                            <subj-group>
                              <subject>SARS CoV 2</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effective vaccine allocation strategies, balancing economy with infection control against COVID-19 in Japan</article-title>
                <alt-title alt-title-type="running-head">Effective vaccine allocation strategies, balancing economy with infection control against COVID-19 in Japan</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Sunohara</surname>
                    <given-names>Satoshi</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Resources</role>
                  <role content-type="https://casrai.org/credit/">Software</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8838-785X</contrib-id>
                  <name>
                    <surname>Asakura</surname>
                    <given-names>Toshiaki</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Resources</role>
                  <role content-type="https://casrai.org/credit/">Software</role>
                  <role content-type="https://casrai.org/credit/">Validation</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6839-8962</contrib-id>
                  <name>
                    <surname>Kimura</surname>
                    <given-names>Takashi</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Project administration</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cor001" ref-type="corresp">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ozawa</surname>
                    <given-names>Shun</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Resources</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Oshima</surname>
                    <given-names>Satoshi</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yamauchi</surname>
                    <given-names>Daigo</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tamakoshi</surname>
                    <given-names>Akiko</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Funding acquisition</role>
                  <role content-type="https://casrai.org/credit/">Project administration</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>School of Medicine, Hokkaido University, Sapporo, Japan</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Public Health, Faculty of Medicine, Hokkaido University, Sapporo, Japan</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Ndeffo Mbah</surname>
                    <given-names>Martial L.</given-names>
                  </name>
                  <role>Editor</role>
                  <xref rid="edit1" ref-type="aff"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Texas A&amp;M University College Station, UNITED STATES</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>kimura@med.hokudai.ac.jp</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>2</day>
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>2</day>
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>16</volume>
              <issue>9</issue>
              <elocation-id>e0257107</elocation-id>
              <history>
                <date date-type="received">
                  <day>13</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>23</day>
                  <month>8</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 Sunohara et al</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Sunohara et al</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pone.0257107.pdf"/>
              <abstract>
                <p>Due to COVID-19, many countries including Japan have implemented a suspension of economic activities for infection control. It has contributed to reduce the transmission of COVID-19 but caused severe economic losses. Today, several promising vaccines have been developed and are already being distributed in some countries. Therefore, we evaluated various vaccine and intensive countermeasure strategies with constraint of economic loss using SEIR model to obtain knowledge of how to balance economy with infection control in Japan. Our main results were that the vaccination strategy that prioritized younger generation was better in terms of deaths when a linear relationship between lockdown intensity and acceptable economic loss was assumed. On the other hand, when a non-linearity relationship was introduced, implying that the strong lockdown with small economic loss was possible, the old first strategies were best in the settings of small basic reproduction number. These results indicated a high potential of remote work when prioritizing vaccination for the old generation. When focusing on only the old first strategies as the Japanese government has decided to do, the strategy vaccinating the young next to the old was superior to the others when a non-linear relationship was assumed due to sufficient reduction of contact with small economic loss.</p>
              </abstract>
              <funding-group>
                <funding-statement>The authors received no specific funding for this work.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="6"/>
                <table-count count="1"/>
                <page-count count="14"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>All relevant data are within the manuscript and its <xref rid="sec009" ref-type="sec">Supporting Information</xref> files.</meta-value>
                </custom-meta>
                <custom-meta id="outbreaks">
                  <meta-name>Outbreaks</meta-name>
                  <meta-value>COVID-19</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>All relevant data are within the manuscript and its <xref rid="sec009" ref-type="sec">Supporting Information</xref> files.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec001">
              <title>Introduction</title>
              <p>At the end of 2019, an outbreak of coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus began in Wuhan City (Hubei Province, China) [<xref rid="pone.0257107.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0257107.ref002" ref-type="bibr">2</xref>]. Over one hundred million people worldwide have been infected with COVID-19 since it was declared to be a pandemic by the World Health Organization on March 11<sup>th</sup>, 2020. As of April 1st, 2021, the death toll was over 2.8 million worldwide and over 9,000 in Japan [<xref rid="pone.0257107.ref003" ref-type="bibr">3</xref>].</p>
              <p>Due to this pandemic, many countries have implemented a suspension of economic activities (usually referred to as a lockdown) with restrictions on movement [<xref rid="pone.0257107.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0257107.ref005" ref-type="bibr">5</xref>]. It has been observed that the implementation of the lockdown reduces contact rate and thus transmission of SARS-CoV-2 [<xref rid="pone.0257107.ref006" ref-type="bibr">6</xref>–<xref rid="pone.0257107.ref009" ref-type="bibr">9</xref>]. On the other hand, lockdowns stopped economic activity and caused severe economic losses [<xref rid="pone.0257107.ref010" ref-type="bibr">10</xref>–<xref rid="pone.0257107.ref012" ref-type="bibr">12</xref>]. In Japan, no enforceable policy of movement restrictions was implemented, but the government declared a state of emergency, not a strict lockdown, to control the spread of SARS-CoV-2. This declaration allowed prefectural governors to take measures such as restricting the operation of public facilities, including schools, and reducing the hours of operation of restaurants [<xref rid="pone.0257107.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0257107.ref014" ref-type="bibr">14</xref>]. This measure resulted in economic losses like lockdown policies in other countries. In the situation of pandemic of COVID-19, the world’s GDP and Japan’s GDP were estimated to have shrunk by 5.2% [<xref rid="pone.0257107.ref015" ref-type="bibr">15</xref>] and by 4.8% [<xref rid="pone.0257107.ref016" ref-type="bibr">16</xref>] in 2020, respectively.</p>
              <p>Today, unlike the situation at the time of the emergence of SARS-CoV-2, several promising vaccines have been developed and are already being distributed in some countries [<xref rid="pone.0257107.ref017" ref-type="bibr">17</xref>]. As of the 15th of June, 20.8% of the world’s population has been vaccinated at least once, especially in many developed countries, where more than 40% of the population has already been vaccinated. However, in low-income countries, only 0.8% of the population has been vaccinated at least once, and vaccination in low-income countries is still an issue. As a consequence, some developed countries like Israel and UK have confirmed a decrease in the number of newly reported case of infection [<xref rid="pone.0257107.ref003" ref-type="bibr">3</xref>]. In Japan, vaccination for healthcare workers has begun in March 2021, and vaccination for the general elderly population has been implemented from April 12th, 2021. However, until herd immunity is established by vaccinating a certain percentage of the population, it is necessary to continue controlling contacts as a preventive measure against infection. This will require knowledge of how to balance economy with infection control under progression of vaccination.</p>
              <p>Therefore, we evaluated various vaccine and intensive countermeasure strategies with constraint of predefined amount of economical loss using SEIR model.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec002">
              <title>Materials and methods</title>
              <sec id="sec003">
                <title>Simulation scenarios</title>
                <p>We assumed that vaccine was started to be distributed at the start of the simulation and that all individuals received vaccination within one year at a constant rate. We used a lockdown as one of intensive countermeasures. Acceptable economic loss was predefined and intensity, length and start timing of the lockdown were optimized to minimize the cumulative number of deaths at the end of the simulation, comparing with different vaccination strategies. It is noted that the lockdown used in this study is defined as countermeasures not only reducing transmissibility but also causing economical damage. Our usage of the lockdown includes containment and closure indicators of OxCGRT indicators [<xref rid="pone.0257107.ref013" ref-type="bibr">13</xref>], for example workplace closing, cancel public events, restrictions on gathering size and stay-at-home requirements. On the other hand, neither countermeasures without economical damage (ex. mask wearing, improving hand hygiene and public information campaign) nor economical supports are included in our usage of the lockdown.</p>
                <p>We divided population into young (15–49 years old), middle (50–64 years old) and old (more than 64-year-old) populations and ignored child age group (0–14 years old) since age was critical factor for contact rates and mortality, and also for simplicity of simulation settings [<xref rid="pone.0257107.ref018" ref-type="bibr">18</xref>]. 10 vaccine allocation strategies were compared in the present study. One scenario was equal allocation for all age groups. 6 scenarios were precise prioritization for 3 generations. For example, old generations were targeted at first. If all old individuals received vaccination, the next target was middle age group. After that, young generations received vaccination. The other 3 scenarios were partial prioritization strategies. One age group was targeted at first and the rest of vaccines were allocated equally to the other two age groups.</p>
                <p>Regarding lockdown strategies, it was assumed that the lockdown was performed only once during each simulation since there was a small chance of resurgence of COVID-19 at the latter phase of the simulation due to vaccination. To balance economy with infection control, we varied three parameters related with the lockdown: start timing, <italic toggle="yes">t</italic><sub>s</sub>, intensity for age group <italic toggle="yes">j</italic>, <italic toggle="yes">L</italic><sub>j</sub>, and length, <italic toggle="yes">T</italic><sub>L</sub>, of the lockdown. In our main analyses, the lockdown was equally imposed to all generations so that <italic toggle="yes">L</italic><sub>j</sub> = <italic toggle="yes">L</italic> for any age group. Simulations with different intensities of the lockdown between generations were performed as a sensitivity analysis.</p>
                <p>Loss of total production value due to the lockdown was defined as economic loss, <italic toggle="yes">E</italic>, expressed as a proportion to the non-lockdown situation and calculated as
<disp-formula id="pone.0257107.e001"><alternatives><graphic xlink:href="pone.0257107.e001.jpg" id="pone.0257107.e001g" position="anchor"/><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:mi>E</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>365</mml:mn></mml:mrow></mml:mfrac><mml:mi>θ</mml:mi><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:msub><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>ϕ</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(1)</label></disp-formula>
where <italic toggle="yes">w</italic><sub>j</sub> and <italic toggle="yes">N</italic><sub>j</sub> was an average production value and the number of populations for age group <italic toggle="yes">j</italic>, respectively. <italic toggle="yes">θ</italic> was defined as lockdown efficacy and we assumed 25% of population would not be affected by the lockdown. We did not consider loss of production caused by any other countermeasures. The relationship between lockdown intensities and economic loss was assumed to be linear (<italic toggle="yes">ϕ</italic> = 0) for the main results. Also, non-linear relationships expressed as a power function were applied. This non-linearity came from the discussion in [<xref rid="pone.0257107.ref019" ref-type="bibr">19</xref>]. In this setting, mild countermeasures against infectious diseases such as teleworking could be taken without significant economic loss, but stronger measures such as the closure of companies to achieve stronger behavioral restraint requirements would result in greater economic loss. Simulations with values of one, two or three for <italic toggle="yes">ϕ</italic> were also performed for the case of the lockdown imposed equally to each age group.</p>
                <p>In addition to analysis with 1.3 of basic reproduction number, <italic toggle="yes">R</italic><sub>0</sub>, we performed sensitivity analysis varying the basic reproduction number. Also, we performed the same analysis with age group specific lockdown intensity, <italic toggle="yes">L</italic><sub>j</sub>, varying <italic toggle="yes">R</italic><sub>0</sub>.</p>
                <p>We estimated parameters, <italic toggle="yes">L</italic><sub>j</sub> and <italic toggle="yes">t</italic><sub>s</sub>, to minimize the cumulative number of deaths. <italic toggle="yes">T</italic><sub>L</sub> were calculated from <italic toggle="yes">L</italic><sub>j</sub> and <italic toggle="yes">E</italic> for each step. Ordinal differential equation was solved by Explicit Runge-Kutta method of order 5(4) [<xref rid="pone.0257107.ref020" ref-type="bibr">20</xref>] and optimization was done with differential evolution implemented in a Python package, Scipy version 1.5.3 [<xref rid="pone.0257107.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0257107.ref022" ref-type="bibr">22</xref>].</p>
              </sec>
              <sec id="sec004">
                <title>SEIR model scheme</title>
                <p>Equations of our SEIR model in the present study are shown as
<disp-formula id="pone.0257107.e002"><alternatives><graphic xlink:href="pone.0257107.e002.jpg" id="pone.0257107.e002g" position="anchor"/><mml:math id="M2" display="block" overflow="scroll"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:math></alternatives><label>(2)</label></disp-formula>
<disp-formula id="pone.0257107.e003"><alternatives><graphic xlink:href="pone.0257107.e003.jpg" id="pone.0257107.e003g" position="anchor"/><mml:math id="M3" display="block" overflow="scroll"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:math></alternatives><label>(3)</label></disp-formula>
<disp-formula id="pone.0257107.e004"><alternatives><graphic xlink:href="pone.0257107.e004.jpg" id="pone.0257107.e004g" position="anchor"/><mml:math id="M4" display="block" overflow="scroll"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>τ</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>−</mml:mo><mml:mi>γ</mml:mi><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:math></alternatives><label>(4)</label></disp-formula>
<disp-formula id="pone.0257107.e005"><alternatives><graphic xlink:href="pone.0257107.e005.jpg" id="pone.0257107.e005g" position="anchor"/><mml:math id="M5" display="block" overflow="scroll"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>γ</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>I</mml:mi><mml:mi>F</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:math></alternatives><label>(5)</label></disp-formula>
<disp-formula id="pone.0257107.e006"><alternatives><graphic xlink:href="pone.0257107.e006.jpg" id="pone.0257107.e006g" position="anchor"/><mml:math id="M6" display="block" overflow="scroll"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>γ</mml:mi><mml:msub><mml:mrow><mml:mi>I</mml:mi><mml:mi>F</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:math></alternatives><label>(6)</label></disp-formula>
<disp-formula id="pone.0257107.e007"><alternatives><graphic xlink:href="pone.0257107.e007.jpg" id="pone.0257107.e007g" position="anchor"/><mml:math id="M7" display="block" overflow="scroll"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>V</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>λ</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:math></alternatives><label>(7)</label></disp-formula>
<disp-formula id="pone.0257107.e008"><alternatives><graphic xlink:href="pone.0257107.e008.jpg" id="pone.0257107.e008g" position="anchor"/><mml:math id="M8" display="block" overflow="scroll"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>V</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>λ</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:math></alternatives><label>(8)</label></disp-formula>
<disp-formula id="pone.0257107.e009"><alternatives><graphic xlink:href="pone.0257107.e009.jpg" id="pone.0257107.e009g" position="anchor"/><mml:math id="M9" display="block" overflow="scroll"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>τ</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>−</mml:mo><mml:mi>γ</mml:mi><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:math></alternatives><label>(9)</label></disp-formula>
<disp-formula id="pone.0257107.e010"><alternatives><graphic xlink:href="pone.0257107.e010.jpg" id="pone.0257107.e010g" position="anchor"/><mml:math id="M10" display="block" overflow="scroll"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>γ</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>V</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>I</mml:mi><mml:mi>F</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:math></alternatives><label>(10)</label></disp-formula>
<disp-formula id="pone.0257107.e011"><alternatives><graphic xlink:href="pone.0257107.e011.jpg" id="pone.0257107.e011g" position="anchor"/><mml:math id="M11" display="block" overflow="scroll"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>γ</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>V</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>I</mml:mi><mml:mi>F</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:math></alternatives><label>(11)</label></disp-formula>
where
<disp-formula id="pone.0257107.e012"><alternatives><graphic xlink:href="pone.0257107.e012.jpg" id="pone.0257107.e012g" position="anchor"/><mml:math id="M12" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>N</mml:mi><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>v</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(12)</label></disp-formula>
and semantics of them are depicted in <xref rid="pone.0257107.g001" ref-type="fig">Fig 1</xref>.</p>
                <fig position="float" id="pone.0257107.g001">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0257107.g001</object-id>
                  <label>Fig 1</label>
                  <caption>
                    <title>Schematic of SEIR model composed of vaccinated and non-vaccinated compartments.</title>
                    <p>Subscript <italic toggle="yes">j</italic> represents young, middle, or old age group. Black shaded box represents death status.</p>
                  </caption>
                  <graphic xlink:href="pone.0257107.g001" position="float"/>
                </fig>
                <p>Our model consisted of contact matrix, infection fatality ratio (IFR) and vaccinated and unvaccinated compartments for simulating infection dynamics of age-stratified populations with vaccination. We refers <italic toggle="yes">S</italic><sub>j,u</sub> and <italic toggle="yes">S</italic><sub>j,v</sub> as unvaccinated and vaccinated susceptible populations of age group <italic toggle="yes">j</italic>. Exposed, infected and recovered populations are similarly defined. Vaccines were distributed at a rate of <italic toggle="yes">N</italic>/<italic toggle="yes">T</italic><sub>vac</sub> for the population and <italic toggle="yes">Np</italic><sub>j</sub>/<italic toggle="yes">T</italic><sub>vac</sub><italic toggle="yes">N</italic><sub>j,u</sub> for each compartment where <italic toggle="yes">N</italic> is total number of the population, <italic toggle="yes">T</italic><sub>vac</sub> is the whole interval of vaccination, and <italic toggle="yes">N</italic><sub>j,u</sub> is total number of unvaccinated population. Vaccine allocation percentage for age group <italic toggle="yes">j</italic>, <italic toggle="yes">p</italic><sub>j</sub> is time-varying parameters taking between 0 to 1 determined by vaccine allocation strategies. For old-other strategies, a mean vaccine allocation percentage for old generation, <italic toggle="yes">p</italic><sub>o,</sub> takes 1 till the end of their vaccination and the others are 0. After that, mean vaccine allocation percentages for young, <italic toggle="yes">p</italic><sub>y</sub>, and middle generations, <italic toggle="yes">p</italic><sub>m</sub>, take percentage of population among two to distribute vaccine according to population size until the whole population is vaccinated. Vaccine effect is assumed to be a leaky one, meaning that vaccinated populations were less likely, not completely, to be infected compared to unvaccinated individuals. Infected and recovered individuals also received vaccination in our model. There are three reasons for this. One reason is that insufficient immunity has been controversial now [<xref rid="pone.0257107.ref023" ref-type="bibr">23</xref>], and that vaccination would contribute to reduce reinfection. The third reason is that it is difficult for asymptomatic cases to be separated from susceptible ones without tests. Death cases are also assumed to be vaccinated in the model to carry out a predetermined vaccination plan.</p>
              </sec>
              <sec id="sec005">
                <title>Force of infection and basic reproduction number</title>
                <p>Force of infection for age group <italic toggle="yes">j</italic>, λ<sub>j</sub>, is an inflow rate from susceptible population to exposed population. Taking lockdown effect into account, force of infection for age group <italic toggle="yes">j</italic> is derived as
<disp-formula id="pone.0257107.e013"><alternatives><graphic xlink:href="pone.0257107.e013.jpg" id="pone.0257107.e013g" position="anchor"/><mml:math id="M13" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>u</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>θ</mml:mi><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:munder></mml:mstyle><mml:mrow><mml:msub><mml:mrow><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>θ</mml:mi><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(13)</label></disp-formula>
where <italic toggle="yes">u</italic> is a successful transmission rate given one contact, and <italic toggle="yes">ρ</italic><sub>jk</sub> is a contact rate for age group <italic toggle="yes">j</italic> with age group <italic toggle="yes">k</italic>.</p>
                <p>The basic reproduction number was calculated from absolute of the dominant eigen value of the matrix <italic toggle="yes">M</italic>, which was the product of a matrix C and a diagonal matrix of which element was <italic toggle="yes">u</italic>/<italic toggle="yes">γ</italic> where 1/<italic toggle="yes">γ</italic> was infectiousness period. The matrix C represents contact matrix weighted by population size which elements were written as <italic toggle="yes">ρ</italic><sub>jk</sub>
<italic toggle="yes">N</italic><sub>k</sub>. This derivation method of <italic toggle="yes">R</italic><sub>0</sub> was described in [<xref rid="pone.0257107.ref024" ref-type="bibr">24</xref>].</p>
              </sec>
              <sec id="sec006">
                <title>Parameter specification</title>
                <p>Parameters used in this study are summarized in <xref rid="pone.0257107.t001" ref-type="table">Table 1</xref>. Most parameters came from resources in Japan in order to perform simulation under the Japanese setting. We had to modify several original data to be compatible with our model, which were contact rates, IFR and production values.</p>
                <table-wrap position="float" id="pone.0257107.t001">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0257107.t001</object-id>
                  <label>Table 1</label>
                  <caption>
                    <title>Summary of parameters used in the simulations.</title>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="pone.0257107.t001" id="pone.0257107.t001g" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">Symbols</th>
                          <th align="left" rowspan="1" colspan="1">Descriptions</th>
                          <th align="left" rowspan="1" colspan="1">Values</th>
                          <th align="left" rowspan="1" colspan="1">References</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <italic toggle="yes">τ</italic>
                          </td>
                          <td align="left" rowspan="1" colspan="1">1/ Latent period (/day).</td>
                          <td align="left" rowspan="1" colspan="1">1/3</td>
                          <td align="left" rowspan="1" colspan="1">[<xref rid="pone.0257107.ref025" ref-type="bibr">25</xref>]</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <italic toggle="yes">γ</italic>
                          </td>
                          <td align="left" rowspan="1" colspan="1">1/ Infectiousness period (/day).</td>
                          <td align="left" rowspan="1" colspan="1">1/5</td>
                          <td align="left" rowspan="1" colspan="1">[<xref rid="pone.0257107.ref026" ref-type="bibr">26</xref>]</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <italic toggle="yes">u</italic>
                          </td>
                          <td align="left" rowspan="1" colspan="1">Transmission rate given one contact.</td>
                          <td align="left" rowspan="1" colspan="1">0.05882 when <italic toggle="yes">R</italic><sub>0</sub> = 1.5</td>
                          <td align="left" rowspan="1" colspan="1">Calculation</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <italic toggle="yes">ρ</italic>
                            <sub>
                              <italic toggle="yes">jk</italic>
                            </sub>
                          </td>
                          <td align="left" rowspan="1" colspan="1">Contact matrix for age group <italic toggle="yes">j</italic> with age group <italic toggle="yes">k</italic>
<xref rid="t001fn001" ref-type="table-fn"><sup>†</sup></xref>.</td>
                          <td align="left" rowspan="1" colspan="1">[[10.482, 1.567, 0.332], [7.250, 3.506, 0.879], [3.105, 1.789, 2.926]]</td>
                          <td align="left" rowspan="1" colspan="1">[<xref rid="pone.0257107.ref027" ref-type="bibr">27</xref>]</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <italic toggle="yes">IFR</italic>
                            <sub>j</sub>
                          </td>
                          <td align="left" rowspan="1" colspan="1">Infection fatality ratio for age group <italic toggle="yes">i</italic> (%) <xref rid="t001fn001" ref-type="table-fn"><sup>†</sup></xref></td>
                          <td align="left" rowspan="1" colspan="1">[0.030, 0.295, 4.893]</td>
                          <td align="left" rowspan="1" colspan="1">[<xref rid="pone.0257107.ref028" ref-type="bibr">28</xref>]</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <italic toggle="yes">N</italic>
                            <sub>j</sub>
                          </td>
                          <td align="left" rowspan="1" colspan="1">Population for age group <italic toggle="yes">j</italic> (×10<sup>3</sup>) <xref rid="t001fn001" ref-type="table-fn"><sup>†</sup></xref>.</td>
                          <td align="left" rowspan="1" colspan="1">[50557, 23987, 36155]</td>
                          <td align="left" rowspan="1" colspan="1">[<xref rid="pone.0257107.ref029" ref-type="bibr">29</xref>]</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">[<italic toggle="yes">E</italic>(0), <italic toggle="yes">I</italic>(0), <italic toggle="yes">R</italic>(0)]</td>
                          <td align="left" rowspan="1" colspan="1">Initial number for E, I and R compartments<xref rid="t001fn002" ref-type="table-fn">*</xref>.</td>
                          <td align="left" rowspan="1" colspan="1">[9540, 18685, 358145]</td>
                          <td align="left" rowspan="1" colspan="1">[<xref rid="pone.0257107.ref030" ref-type="bibr">30</xref>]</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <italic toggle="yes">θ</italic>
                          </td>
                          <td align="left" rowspan="1" colspan="1">Lockdown efficiency.</td>
                          <td align="left" rowspan="1" colspan="1">0.75</td>
                          <td align="left" rowspan="1" colspan="1">Assumption</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <italic toggle="yes">w</italic>
                            <sub>j</sub>
                          </td>
                          <td align="left" rowspan="1" colspan="1">Production value for age group <italic toggle="yes">j</italic> (×10<sup>3</sup> yen) <xref rid="t001fn001" ref-type="table-fn"><sup>†</sup></xref>.</td>
                          <td align="left" rowspan="1" colspan="1">[3742, 4474, 812]</td>
                          <td align="left" rowspan="1" colspan="1">[<xref rid="pone.0257107.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0257107.ref032" ref-type="bibr">32</xref>]</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <italic toggle="yes">VE</italic>
                            <sub>
                              <italic toggle="yes">λ</italic>
                            </sub>
                          </td>
                          <td align="left" rowspan="1" colspan="1">Vaccine efficacy for transmission.</td>
                          <td align="left" rowspan="1" colspan="1">0.95</td>
                          <td align="left" rowspan="1" colspan="1">[<xref rid="pone.0257107.ref033" ref-type="bibr">33</xref>]</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">
                            <italic toggle="yes">VE</italic>
                            <sub>
                              <italic toggle="yes">d</italic>
                            </sub>
                          </td>
                          <td align="left" rowspan="1" colspan="1">Vaccine efficacy for death.</td>
                          <td align="left" rowspan="1" colspan="1">0.84</td>
                          <td align="left" rowspan="1" colspan="1">[<xref rid="pone.0257107.ref034" ref-type="bibr">34</xref>]</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t001fn001">
                      <p><sup>†</sup> The order of values listed is young, middle and old age group.</p>
                    </fn>
                    <fn id="t001fn002">
                      <p>* These values were assigned to each age group proportional to population size.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>To truncate the original data to the values used in the model, we denote <italic toggle="yes">x</italic><sub>5i,5j</sub> as contact rates of a person among <italic toggle="yes">5i</italic> to <italic toggle="yes">5(i+1) -1</italic> age interval with a person among <italic toggle="yes">5j</italic> to <italic toggle="yes">5(j+1) -1</italic> age interval and <italic toggle="yes">N</italic><sub>5i</sub> represents population size for <italic toggle="yes">5i</italic> to <italic toggle="yes">5(i+1) -1</italic> years old since original data had 5-year interval values. We combined rows for each age interval and took weighted summarization for columns by population size. For example, contact rate of young group with middle group, <italic toggle="yes">ρ</italic><sub>ym</sub>, was calculated as
<disp-formula id="pone.0257107.e014"><alternatives><graphic xlink:href="pone.0257107.e014.jpg" id="pone.0257107.e014g" position="anchor"/><mml:math id="M14" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>y</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:msubsup><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:msubsup><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mn>5</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:msubsup><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(14)</label></disp-formula>
where contact rates for young with middle age group were summed over from 50–54 to 60–64 age interval and were weighted by each age interval from 15–19 to 45–49 age interval. Similar calculation was done for other age group pairs, noting that we ignored population from 0 to 14 years old. The contact rates of the reference paper [<xref rid="pone.0257107.ref027" ref-type="bibr">27</xref>] did not have the ones of age more than 79 years old, so that we copied rows and columns of 75–79 years old diagonally. We multiplied 0.9 for these rows and columns since we considered older populations had lower contact rate than that of 75–79 years.</p>
                <p>The reference of IFR [<xref rid="pone.0257107.ref028" ref-type="bibr">28</xref>] showed that the relationship between IFR and age was exponential. Since we were able to calculate infection fatality ratio at any age using this relationship, IFR of each age group was calculated as weighted means of IFR for each 5-age interval. For example, the equation for young age group was derived as
<disp-formula id="pone.0257107.e015"><alternatives><graphic xlink:href="pone.0257107.e015.jpg" id="pone.0257107.e015g" position="anchor"/><mml:math id="M15" display="block" overflow="scroll"><mml:mrow><mml:mi>I</mml:mi><mml:mi>F</mml:mi><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:msubsup><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>I</mml:mi><mml:mi>F</mml:mi><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:msubsup><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(15)</label></disp-formula>
where <italic toggle="yes">IFR</italic><sub>5i+2</sub> represents the infection fatality rate at age <italic toggle="yes">5i +2</italic>, which is a median of each age interval. For old age group, more than 80 years old were grouped as one and we chose IFR at 85 years old for this group.</p>
                <p>Production value was intended to reflect production values by workers. We obtained values of salary for each 5-age intervals, and weighted summaries by population size were used for production value for each age group, <italic toggle="yes">w</italic><sub>j</sub>.</p>
                <p>We set the initial number of each SEIR component as the status on 1st February 2021 in Japan. We set initial value for <italic toggle="yes">E</italic><sub>j</sub> as sum of newly reported cases during 29th to 31st January 2021 multiplied by a percentage of population size for age group <italic toggle="yes">j</italic> and for <italic toggle="yes">I</italic><sub>j</sub> and R<sub>j</sub> as sum of ones during 23rd to 28th January 2021 and the cumulative number of cases till 22nd January 2021, respectively, multiplied by the same percentage. Actual values can be seen in <xref rid="pone.0257107.t001" ref-type="table">Table 1</xref>.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec007">
              <title>Results</title>
              <p><xref rid="pone.0257107.g002" ref-type="fig">Fig 2</xref> illustrates the relationship between economic loss and lockdown intensity and length values. x and y axis represent intensity and length of the lockdown and z axis represents the cumulative number of deaths at the end of the simulation. Optimization of parameters (<italic toggle="yes">T</italic><sub>L</sub>, <italic toggle="yes">L</italic> and <italic toggle="yes">t</italic><sub>s</sub>) for the lockdown imposing equally to each age group was done along each line drawn by constraint of predefined economic loss value, <italic toggle="yes">E</italic>. The start timing of the lockdown, <italic toggle="yes">t</italic><sub>s</sub>, was estimated to be 0<sup>th</sup> day for almost all simulations. <italic toggle="yes">t</italic><sub>s</sub> was estimated to be more than 0<sup>th</sup> day (sometimes around 70<sup>th</sup> day) when <italic toggle="yes">ϕ</italic> took a value of 0, <italic toggle="yes">R</italic><sub>0</sub> was higher, economic losses were lower, and the strategies were the middle first ones, the old first ones, or the equal strategy. In the case of a value of <italic toggle="yes">ϕ</italic> more than zero, <italic toggle="yes">t</italic><sub>s</sub> was estimated to be 0<sup>th</sup> day for all cases. Then, we omitted the value of <italic toggle="yes">t</italic><sub>s</sub> from the following figures.</p>
              <fig position="float" id="pone.0257107.g002">
                <object-id pub-id-type="doi">10.1371/journal.pone.0257107.g002</object-id>
                <label>Fig 2</label>
                <caption>
                  <title>Illustration of relationship between economic loss and lockdown intensity and length values.</title>
                  <p>x and y axis represent lockdown intensity and length values. z axis represents the cumulative number of deaths at the end of the simulations. Each line was drawn with the same volume of economic loss, <italic toggle="yes">E</italic>. Points show the minimum cumulative number of deaths for each line. Values at these points were used for the optimized parameters and shown in the following figures.</p>
                </caption>
                <graphic xlink:href="pone.0257107.g002" position="float"/>
              </fig>
              <p><xref rid="pone.0257107.g003" ref-type="fig">Fig 3</xref> summarizes the cumulative number of deaths and infected population at the end of the simulations under 10 vaccine allocation strategies for each acceptable economic loss, together with the lockdown intensity and length giving optimal results (see <xref rid="pone.0257107.s006" ref-type="supplementary-material">S1 Table</xref> for detail). The lockdown was equally imposed to all generations, the basic reproduction number, <italic toggle="yes">R</italic><sub>0</sub>, was set to be 1.3 and <italic toggle="yes">ϕ</italic> took zero. Overall, three young first strategies were the most effective in reducing the number of deaths and infections for most of the cases. The fourth effective strategy would be one that distributed vaccine equally to all age groups, especially in lower acceptable economic loss. The strong lockdown with short interval was preferable for young first strategies since young population had high contact rates. Restricting and vaccinating this population simultaneously leaded to lower reproduction number.</p>
              <fig position="float" id="pone.0257107.g003">
                <object-id pub-id-type="doi">10.1371/journal.pone.0257107.g003</object-id>
                <label>Fig 3</label>
                <caption>
                  <title>The optimized results and parameters for R0 = 1.3 and <italic toggle="yes">ϕ</italic> = 0 when the lockdown was imposed equally to each generation.</title>
                  <p>The optimized results of the cumulative number of deaths (A) and infected (B) populations for each economic loss. (C) and (D) represents the lockdown intensity and length, which value pattern produced the results of (A) and (B) for each economic loss. Although there are only eight lines visible in (A) and (B), three lines of young first vaccination strategies have overlain each other. The order of age groups on the label shows vaccine allocation strategies.</p>
                </caption>
                <graphic xlink:href="pone.0257107.g003" position="float"/>
              </fig>
              <p>The cumulative numbers of the deaths for all strategies under 4 patterns of the basic reproduction number when <italic toggle="yes">ϕ</italic> took zero are shown in <xref rid="pone.0257107.g004" ref-type="fig">Fig 4</xref>. The best strategies were young first ones in terms of the cumulative number of deaths or infected population regardless of <italic toggle="yes">R</italic><sub>0</sub> except the strong lockdown situation. In addition, the strategy distributing vaccine equally to all age groups was the fourth effective strategy in most sizes of economic losses under 1.5 of <italic toggle="yes">R</italic><sub>0</sub>. However, when <italic toggle="yes">R</italic><sub>0</sub> was more than around 1.5, in situations where the lockdown was mild and caused little economic loss, three old first strategies were more effective than those of vaccinating all generations equally in terms of deaths. When comparing strategies prioritizing vaccination to the old or middle age group, the old first strategies were more effective when the lockdown caused little economic loss, while the middle first strategies were more effective when there was much economic loss due to the lockdown. The differences in the effectiveness of the middle and old first strategies were more apparent for larger values of <italic toggle="yes">R</italic><sub>0</sub>.</p>
              <fig position="float" id="pone.0257107.g004">
                <object-id pub-id-type="doi">10.1371/journal.pone.0257107.g004</object-id>
                <label>Fig 4</label>
                <caption>
                  <title>The cumulative number of deaths with R0 taking 1.3, 1.5, 1.7 and 1.9 and <italic toggle="yes">ϕ</italic> = 0 when the lockdown was imposed equally to each generation.</title>
                  <p>Each line shows vaccine allocation strategies. Three lines of young first vaccination strategies have overlain each other.</p>
                </caption>
                <graphic xlink:href="pone.0257107.g004" position="float"/>
              </fig>
              <p>The heatmap of the best strategies in terms of the cumulative number of deaths among the old strategies showed that early vaccination for the young (specifically the young-old-middle strategy) was most effective in reducing the number of deaths when <italic toggle="yes">ϕ</italic> was zero (<xref rid="pone.0257107.g005" ref-type="fig">Fig 5</xref>). However, as <italic toggle="yes">ϕ</italic> increased, the old first strategies were best strategies in case of low <italic toggle="yes">R</italic><sub>0</sub> and higher acceptable economic losses. Particularly, for the case where <italic toggle="yes">R</italic><sub>0</sub> was small and the acceptable economic loss was large, the old first strategies was clearly best strategies among all when <italic toggle="yes">ϕ</italic> took three (<xref rid="pone.0257107.s001" ref-type="supplementary-material">S1 Fig</xref>).</p>
              <fig position="float" id="pone.0257107.g005">
                <object-id pub-id-type="doi">10.1371/journal.pone.0257107.g005</object-id>
                <label>Fig 5</label>
                <caption>
                  <title>Heatmap of the best strategies in terms of the cumulative number of deaths among all strategies varying <italic toggle="yes">ϕ</italic>, R0 and acceptable economic losses.</title>
                </caption>
                <graphic xlink:href="pone.0257107.g005" position="float"/>
              </fig>
              <p>As Japan has already decided to vaccinate to the old age groups first, we compared three old first strategies in order to clarify which order of vaccination was better after the old age group was vaccinated. <xref rid="pone.0257107.g006" ref-type="fig">Fig 6</xref> summarizes the best old first strategy among three strategies, old-middle-young, old-young-middle, and old-other strategies, varying <italic toggle="yes">ϕ</italic> and <italic toggle="yes">R</italic><sub>0</sub> (see <xref rid="pone.0257107.s007" ref-type="supplementary-material">S2 Table</xref> for detail). When <italic toggle="yes">R</italic><sub>0</sub> was below 1.4 and <italic toggle="yes">ϕ</italic> took zero, the old-young-middle strategy was most effective in reducing deaths under almost all the economic loss patterns, whereas under larger <italic toggle="yes">R</italic><sub>0</sub>, the old-middle-young strategy started to excel greater than the other strategies for low acceptable economic loss. For the value of <italic toggle="yes">ϕ</italic> more than zero, the old-young-middle strategy was the best for the almost all the cases. Especially, if <italic toggle="yes">ϕ</italic> took three, the old-young-middle strategy was best for all the settings.</p>
              <fig position="float" id="pone.0257107.g006">
                <object-id pub-id-type="doi">10.1371/journal.pone.0257107.g006</object-id>
                <label>Fig 6</label>
                <caption>
                  <title>Heatmap of the best strategies in terms of the cumulative number of deaths among the old first strategies varying <italic toggle="yes">ϕ</italic>, R0 and acceptable economic losses.</title>
                </caption>
                <graphic xlink:href="pone.0257107.g006" position="float"/>
              </fig>
              <p>We also performed simulations under settings of the lockdown being imposed with different intensities to each age group for 1.3 of <italic toggle="yes">R</italic><sub>0</sub> (<xref rid="pone.0257107.s002" ref-type="supplementary-material">S2</xref> and <xref rid="pone.0257107.s003" ref-type="supplementary-material">S3</xref> Figs) and varying <italic toggle="yes">R</italic><sub>0</sub> (<xref rid="pone.0257107.s004" ref-type="supplementary-material">S4</xref> and <xref rid="pone.0257107.s005" ref-type="supplementary-material">S5</xref> Figs) when <italic toggle="yes">ϕ</italic> took zero. Over all trends of the cumulative number of deaths and infected population were similar as when the lockdown was equally imposed. One exception was when <italic toggle="yes">R</italic><sub>0</sub> took 2.0 and economic loss was 0.5% and the best strategy was old-middle-young strategy (<xref rid="pone.0257107.s005" ref-type="supplementary-material">S5 Fig</xref>). To achieve optimal strategies, the strong lockdown to young and old age group was preferable compared to middle age group.</p>
            </sec>
            <sec sec-type="conclusions" id="sec008">
              <title>Discussion</title>
              <p>We explored the better vaccine allocation and intensive countermeasure strategies to balance economic sustainability with infection control against COVID-19 in Japan. The young first strategies (specifically the young-old-middle strategy) were better than any other strategies in lower acceptable economic loss and moderate to higher <italic toggle="yes">R</italic><sub>0</sub> when a linear relationship between lockdown intensity and acceptable economic losses (<italic toggle="yes">ϕ</italic> = 0) was assumed (<xref rid="pone.0257107.g005" ref-type="fig">Fig 5</xref>). If we applied a non-linear relationship expressed as a power function, which implied a large potential for reducing contact without economic loss, the old first strategy (specifically the old-young-middle strategy) became the best when lower <italic toggle="yes">R</italic><sub>0</sub>. These results were obtained because the spread of infection was suppressed only by lockdown, and as a result, the effect of early vaccination of the young on the prevention of the spread of infection was diminished, and instead the effect of early vaccination of the elderly on the reduction of mortality was greatly contributed. These results indicated a high potential of remote work when prioritizing vaccination for the old generation.</p>
              <p>If we focused on the old first strategies, as the Japan government has decided to vaccinate the old populations first, the old-young-middle strategy was the best for almost all the cases for <italic toggle="yes">ϕ</italic> more than zero (<xref rid="pone.0257107.g006" ref-type="fig">Fig 6</xref>). These results came from the fact that young age group had the highest contact rates for all age groups [<xref rid="pone.0257107.ref025" ref-type="bibr">25</xref>] and was more likely to transmit infection so that vaccinating young populations at an early stage would prevent them from transmitting infection and enable population to reach herd immunity at the early stage, resulting in the containment of the epidemic and reduction of deaths. Also, the non-linear relationship would contribute to containments of the epidemics and the role of vaccination came to be a containment of the epidemic.</p>
              <p>Our results implied that the best strategy minimizing deaths was changed according to the value of <italic toggle="yes">R</italic><sub>0</sub> and how countermeasures causing economical damage was imposed. <italic toggle="yes">R</italic><sub>0</sub> of COVID-19 was estimated as more than 2 at early stage of the epidemic [<xref rid="pone.0257107.ref035" ref-type="bibr">35</xref>, <xref rid="pone.0257107.ref036" ref-type="bibr">36</xref>]. However, effective case tracing [<xref rid="pone.0257107.ref026" ref-type="bibr">26</xref>, <xref rid="pone.0257107.ref037" ref-type="bibr">37</xref>] and much public awareness reduced transmissibility and some study handling with negative values of serial interval reported lower value of <italic toggle="yes">R</italic><sub>0</sub> [<xref rid="pone.0257107.ref038" ref-type="bibr">38</xref>]. Also, our usage of a lockdown does not include countermeasures without economical damage, which will lead to lower <italic toggle="yes">R</italic><sub>0</sub>. However, a new SARS-CoV-2 variant, VOC 202012/01 was reported to be 43–90% higher transmissibility than preexisting variants [<xref rid="pone.0257107.ref039" ref-type="bibr">39</xref>, <xref rid="pone.0257107.ref040" ref-type="bibr">40</xref>] and has been appeared also in Japan. It indicates higher <italic toggle="yes">R</italic><sub>0</sub> setting is better for our results. As shown in <xref rid="pone.0257107.g004" ref-type="fig">Fig 4</xref>, as <italic toggle="yes">R</italic><sub>0</sub> increased, number of deaths increased exponentially, so that strategies should be chosen by assuming the worst.</p>
              <p>Since we used relative volume of population size and salary for each age group for calculation of economic loss, <italic toggle="yes">E</italic>, comparison with other metrics can be done. The annual GDP growth rates for 2019 and 2020 were 0.3% and -4.8%, respectively [<xref rid="pone.0257107.ref016" ref-type="bibr">16</xref>]. If we focus on the quarterly GDP growth in 2020, these values are -0.6%, -8.3%, 5.3% and 2.8% from the earliest to the latest. If this volume of decline is totally caused from countermeasures and contributes to reduce transmissibility, sufficient decline can be achieved. However, there are many measures to reduce transmissibility without economical damage so that raising each person’s awareness of infection control is important.</p>
              <p>While our analysis assumed that the entire population would eventually be vaccinated in one year, this assumption would not be accurate in terms of vaccination rate and final percentage of vaccination. Also, vaccination efficacy for transmissibility and deaths were not accurately evaluated [<xref rid="pone.0257107.ref034" ref-type="bibr">34</xref>] and how long its immunity sustains and how protective for new strains it is remains unknown.</p>
              <p>As for a lockdown, its intensity in the present study was assumed to be precisely controlled by policy makers but in practice the actual extent of the contact reduction may not be obvious until a lockdown is in practice. Although the one-time lockdown assumption was adopted in this study, this implementation should be caution in the real-world settings. The simple SEIR model study [<xref rid="pone.0257107.ref019" ref-type="bibr">19</xref>] showed constant strong lockdown strategy was not optimal if the vaccination was started at the end of the simulation. The gradual relaxation strategy was preferred, and this strategy was conducted in the UK and Israel during vaccination. For the lockdown with age-specific intensities, the results were not much changed from the lockdown with the same intensity to all age groups (<xref rid="pone.0257107.s005" ref-type="supplementary-material">S5 Fig</xref>). The one exceptional result in <xref rid="pone.0257107.s005" ref-type="supplementary-material">S5 Fig</xref> when <italic toggle="yes">R</italic><sub>0</sub> took 2.0 and economic loss was 0.5% indicated old-first strategy started to beat other strategies in case of higher <italic toggle="yes">R</italic><sub>0</sub> with weak lockdown.</p>
              <p>There are several limitations to our study. First, although the results of this study relied highly on parameters, especially contact rates, the contact rates referred to in the present study were based on data from [<xref rid="pone.0257107.ref027" ref-type="bibr">27</xref>], which did not take into account behavioral changes brought about by the COVID-19 pandemic. Second, our analysis excluded children aged from 0 to 15 years old. Several studies suggested children were less likely to contribute to epidemics [<xref rid="pone.0257107.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0257107.ref040" ref-type="bibr">40</xref>–<xref rid="pone.0257107.ref042" ref-type="bibr">42</xref>], the number of children cases has been increasing due to a new variant of SARS-CoV-2. Third, our model of economic loss considered only the impact of direct behavioral restraint due to the lockdown, and did not take into account the value that infectious disease victims were expected to produce in the future, which had been taken into account in several previous studies about economic losses by COVID-19 pandemic [<xref rid="pone.0257107.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0257107.ref043" ref-type="bibr">43</xref>]. Finally, since the calculations in this study were based on the population structure and contact rates in Japan, the results obtained in this study are not directly applicable to the situation of foreign countries.</p>
            </sec>
            <sec id="sec009" sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="pone.0257107.s001" position="float" content-type="local-data">
                <label>S1 Fig</label>
                <caption>
                  <title>The cumulative number of deaths with <italic toggle="yes">R</italic><sub>0</sub> taking 1.3, 1.5, 1.7 and 1.9 and <italic toggle="yes">ϕ</italic> taking 1, 2, and 3 when the lockdown was imposed equally to each generation.</title>
                  <p>Each line shows vaccine allocation strategies. Three lines of young first vaccination strategies have overlain each other.</p>
                  <p>(TIF)</p>
                </caption>
                <media xlink:href="pone.0257107.s001.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pone.0257107.s002" position="float" content-type="local-data">
                <label>S2 Fig</label>
                <caption>
                  <title>The optimized results for <italic toggle="yes">R</italic><sub>0</sub> = 1.3 when the lockdown was imposed with different intensities to each age group.</title>
                  <p>The optimized results of the cumulative number of deaths and infected population for each economic loss is presented. Three lines of young first vaccination strategies have overlain each other. The order of age groups on the label shows vaccine allocation strategies.</p>
                  <p>(TIF)</p>
                </caption>
                <media xlink:href="pone.0257107.s002.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pone.0257107.s003" position="float" content-type="local-data">
                <label>S3 Fig</label>
                <caption>
                  <title>The optimized parameters for <italic toggle="yes">R</italic><sub>0</sub> = 1.3 when the lockdown was imposed with different intensities to each age group.</title>
                  <p>Each figure block contains lockdown intensities for young (blue), middle (yellow) and old (green) age group and lockdown length (red). It is noted that y axis represented lockdown intensity and lockdown length.</p>
                  <p>(TIF)</p>
                </caption>
                <media xlink:href="pone.0257107.s003.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pone.0257107.s004" position="float" content-type="local-data">
                <label>S4 Fig</label>
                <caption>
                  <title>The cumulative number of deaths with <italic toggle="yes">R</italic><sub>0</sub> taking 1.3, 1.5, 1.7 and 1.9, and <italic toggle="yes">ϕ</italic> = 0 when the lockdown was imposed with different intensities to each age group.</title>
                  <p>Each line shows vaccine allocation strategies. Three lines of young first vaccination strategies have overlain each other.</p>
                  <p>(TIF)</p>
                </caption>
                <media xlink:href="pone.0257107.s004.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pone.0257107.s005" position="float" content-type="local-data">
                <label>S5 Fig</label>
                <caption>
                  <title>Heatmap of the best strategy in terms of the cumulative number of deaths among all strategies varying <italic toggle="yes">R</italic><sub>0</sub> and acceptable economic losses when the lockdown was imposed with different intensities to each age group.</title>
                  <p>(TIF)</p>
                </caption>
                <media xlink:href="pone.0257107.s005.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pone.0257107.s006" position="float" content-type="local-data">
                <label>S1 Table</label>
                <caption>
                  <title>Numerical results for the beset strategy among all to minimize the cumulative number of deaths imposing same intensity of the lockdown to all age groups.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0257107.s006.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pone.0257107.s007" position="float" content-type="local-data">
                <label>S2 Table</label>
                <caption>
                  <title>Numerical results for the beset strategy among the three old first strategies to minimize the cumulative number of deaths imposing same intensity of the lockdown to all age groups.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0257107.s007.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>We thank for Yusuke Asai for valuable technical advice and useful discussions.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="pone.0257107.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>N</given-names></name>, <name><surname>Zhang</surname><given-names>D</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Yang</surname><given-names>B</given-names></name>, <name><surname>Song</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>A Novel Coronavirus from Patients with Pneumonia in China, 2019</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>: <fpage>727</fpage>–<lpage>733</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id><pub-id pub-id-type="pmid">31978945</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>R</given-names></name>, <name><surname>Zhao</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Niu</surname><given-names>P</given-names></name>, <name><surname>Yang</surname><given-names>B</given-names></name>, <name><surname>Wu</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title>. <source>The Lancet</source>. <year>2020</year>;<volume>395</volume>: <fpage>565</fpage>–<lpage>574</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref003">
                <label>3</label>
                <mixed-citation publication-type="other">WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard. [cited 1 Apr 2021]. Available: <ext-link xlink:href="https://covid19.who.int/" ext-link-type="uri">https://covid19.who.int/</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Tian</surname><given-names>H</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Wu</surname><given-names>C-H</given-names></name>, <name><surname>Chen</surname><given-names>B</given-names></name>, <name><surname>Kraemer</surname><given-names>MUG</given-names></name>, <etal>et al</etal>. <article-title>An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China.</article-title><source>Science</source>. <year>2020</year>;<volume>368</volume>: <fpage>638</fpage>–<lpage>642</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.abb6105</pub-id><pub-id pub-id-type="pmid">32234804</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><collab>Imperial College COVID-19 Response Team</collab>, <name><surname>Flaxman</surname><given-names>S</given-names></name>, <name><surname>Mishra</surname><given-names>S</given-names></name>, <name><surname>Gandy</surname><given-names>A</given-names></name>, <name><surname>Unwin</surname><given-names>HJT</given-names></name>, <name><surname>Mellan</surname><given-names>TA</given-names></name>, <etal>et al</etal>. <article-title>Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.</article-title><source>Nature</source>. <year>2020</year>;<volume>584</volume>: <fpage>257</fpage>–<lpage>261</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-020-2405-7</pub-id><pub-id pub-id-type="pmid">32512579</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Hyafil</surname><given-names>A</given-names></name>, <name><surname>Moriña</surname><given-names>D</given-names></name>. <article-title>Analysis of the impact of lockdown on the reproduction number of the SARS-Cov-2 in Spain.</article-title><source>Gaceta Sanitaria.</source><year>2020</year>; S0213911120300984. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.gaceta.2020.05.003</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Alfano</surname><given-names>V</given-names></name>, <name><surname>Ercolano</surname><given-names>S</given-names></name>. <article-title>The Efficacy of Lockdown Against COVID-19: A Cross-Country Panel Analysis.</article-title><source>Appl Health Econ Health Policy.</source><year>2020</year>;<volume>18</volume>: <fpage>509</fpage>–<lpage>517</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s40258-020-00596-3</pub-id><pub-id pub-id-type="pmid">32495067</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Caristia</surname><given-names>S</given-names></name>, <name><surname>Ferranti</surname><given-names>M</given-names></name>, <name><surname>Skrami</surname><given-names>E</given-names></name>, <name><surname>Raffetti</surname><given-names>E</given-names></name>, <name><surname>Pierannunzio</surname><given-names>D</given-names></name>, <name><surname>Palladino</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Effect of national and local lockdowns on the control of COVID-19 pandemic: a rapid review.</article-title><source>E&amp;P.</source><year>2020</year>;<volume>44</volume>: <fpage>60</fpage>–<lpage>68</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.19191/EP20.5-6.S2.104</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Ambikapathy</surname><given-names>B</given-names></name>, <name><surname>Krishnamurthy</surname><given-names>K</given-names></name>. <article-title>Mathematical Modelling to Assess the Impact of Lockdown on COVID-19 Transmission in India: Model Development and Validation.</article-title><source>JMIR Public Health Surveill</source>. <year>2020</year>;<volume>6</volume>: <fpage>e19368</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2196/19368</pub-id><pub-id pub-id-type="pmid">32365045</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>You</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>M</given-names></name>, <name><surname>Song</surname><given-names>H</given-names></name>, <name><surname>Xu</surname><given-names>X</given-names></name>, <name><surname>Lai</surname><given-names>Y</given-names></name>. <article-title>Assessment of monthly economic losses in Wuhan under the lockdown against COVID-19.</article-title><source>Humanit Soc Sci Commun</source>. <year>2020</year>;<volume>7</volume>: <fpage>52</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1057/s41599-020-00545-4</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Nurchis</surname><given-names>MC</given-names></name>, <name><surname>Pascucci</surname><given-names>D</given-names></name>, <name><surname>Sapienza</surname><given-names>M</given-names></name>, <name><surname>Villani</surname><given-names>L</given-names></name>, <name><surname>D’Ambrosio</surname><given-names>F</given-names></name>, <name><surname>Castrini</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Impact of the Burden of COVID-19 in Italy: Results of Disability-Adjusted Life Years (DALYs) and Productivity Loss.</article-title><source>IJERPH.</source><year>2020</year>;<volume>17</volume>: <fpage>4233</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijerph17124233</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Mottaleb</surname><given-names>KA</given-names></name>, <name><surname>Mainuddin</surname><given-names>M</given-names></name>, <name><surname>Sonobe</surname><given-names>T</given-names></name>. <article-title>COVID-19 induced economic loss and ensuring food security for vulnerable groups: Policy implications from Bangladesh.</article-title><name><surname>Zereyesus</surname><given-names>Y</given-names></name>, editor. <source>PLoS ONE.</source><year>2020</year>;<volume>15</volume>: <fpage>e0240709</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0240709</pub-id><pub-id pub-id-type="pmid">33064771</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Hale</surname><given-names>T</given-names></name>, <name><surname>Angrist</surname><given-names>N</given-names></name>, <name><surname>Goldszmidt</surname><given-names>R</given-names></name>, <name><surname>Kira</surname><given-names>B</given-names></name>, <name><surname>Petherick</surname><given-names>A</given-names></name>, <name><surname>Phillips</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker).</article-title><source>Nat Hum Behav.</source><year>2021</year> [cited 29 Mar 2021]. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41562-021-01079-8</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Tan-Torres Edejer</surname><given-names>T</given-names></name>, <name><surname>Hanssen</surname><given-names>O</given-names></name>, <name><surname>Mirelman</surname><given-names>A</given-names></name>, <name><surname>Verboom</surname><given-names>P</given-names></name>, <name><surname>Lolong</surname><given-names>G</given-names></name>, <name><surname>Watson</surname><given-names>OJ</given-names></name>, <etal>et al</etal>. <article-title>Projected health-care resource needs for an effective response to COVID-19 in 73 low-income and middle-income countries: a modelling study</article-title>. <source>The Lancet Global Health</source>. <year>2020</year>;<volume>8</volume>: <fpage>e1372</fpage>–<lpage>e1379</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S2214-109X(20)30383-1</pub-id><pub-id pub-id-type="pmid">32918872</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref015">
                <label>15</label>
                <mixed-citation publication-type="other">The Global Economic Outlook During the COVID-19 Pandemic: A Changed World. In: World Bank [Internet]. [cited 1 Apr 2021]. Available: <ext-link xlink:href="https://www.worldbank.org/en/news/feature/2020/06/08/the-global-economic-outlook-during-the-covid-19-pandemic-a-changed-world" ext-link-type="uri">https://www.worldbank.org/en/news/feature/2020/06/08/the-global-economic-outlook-during-the-covid-19-pandemic-a-changed-world</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref016">
                <label>16</label>
                <mixed-citation publication-type="other">Cabinet Office. System of National Accounts. [cited 1 Apr 2021]. Available: <ext-link xlink:href="https://www.esri.cao.go.jp/jp/sna/menu.html" ext-link-type="uri">https://www.esri.cao.go.jp/jp/sna/menu.html</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref017">
                <label>17</label>
                <mixed-citation publication-type="other">Coronavirus (COVID-19) Vaccinations—Statistics and Research. In: Our World in Data [Internet]. [cited 1 Apr 2021]. Available: <ext-link xlink:href="https://ourworldindata.org/covid-vaccinations" ext-link-type="uri">https://ourworldindata.org/covid-vaccinations</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref018">
                <label>18</label>
                <mixed-citation publication-type="book"><name><surname>Acemoglu</surname><given-names>D</given-names></name>, <name><surname>Chernozhukov</surname><given-names>V</given-names></name>, <name><surname>Werning</surname><given-names>I</given-names></name>, <name><surname>Whinston</surname><given-names>M</given-names></name>. <source>Optimal Targeted Lockdowns in a Multi-Group SIR Model</source>. <publisher-loc>Cambridge, MA</publisher-loc>: <publisher-name>National Bureau of Economic Research</publisher-name>; <year>2020</year><month>May</month> p. <fpage>w27102</fpage>. Report No.: w27102. <comment>doi: </comment><pub-id pub-id-type="doi">10.3386/w27102</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Rowthorn</surname><given-names>R</given-names></name>, <name><surname>Maciejowski</surname><given-names>J</given-names></name>. <article-title>A cost–benefit analysis of the COVID-19 disease.</article-title><source>Oxford Review of Economic Policy</source>. <year>2020</year>;<volume>36</volume>: <fpage>S38</fpage>–<lpage>S55</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/oxrep/graa030</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Dormand</surname><given-names>JR</given-names></name>, <name><surname>Prince</surname><given-names>PJ</given-names></name>. <article-title>A family of embedded Runge-Kutta formulae</article-title>. <source>Journal of Computational and Applied Mathematics</source>. <year>1980</year>;<volume>6</volume>: <fpage>19</fpage>–<lpage>26</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0771-050X(80)90013-3</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><collab>SciPy 1.0 Contributors</collab>, <name><surname>Virtanen</surname><given-names>P</given-names></name>, <name><surname>Gommers</surname><given-names>R</given-names></name>, <name><surname>Oliphant</surname><given-names>TE</given-names></name>, <name><surname>Haberland</surname><given-names>M</given-names></name>, <name><surname>Reddy</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>SciPy 1.0: fundamental algorithms for scientific computing in Python.</article-title><source>Nat Methods</source>. <year>2020</year>;<volume>17</volume>: <fpage>261</fpage>–<lpage>272</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41592-019-0686-2</pub-id><pub-id pub-id-type="pmid">32015543</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Storn</surname><given-names>R</given-names></name>, <name><surname>Price</surname><given-names>K</given-names></name>. <article-title>Differential Evolution–A Simple and Efficient Heuristic for global Optimization over Continuous Spaces</article-title>. <source>Journal of Global Optimization</source>. <year>1997</year>;<volume>11</volume>: <fpage>341</fpage>–<lpage>359</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1023/A:1008202821328</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Tillett</surname><given-names>RL</given-names></name>, <name><surname>Sevinsky</surname><given-names>JR</given-names></name>, <name><surname>Hartley</surname><given-names>PD</given-names></name>, <name><surname>Kerwin</surname><given-names>H</given-names></name>, <name><surname>Crawford</surname><given-names>N</given-names></name>, <name><surname>Gorzalski</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Genomic evidence for reinfection with SARS-CoV-2: a case study</article-title>. <source>The Lancet Infectious Diseases</source>. <year>2021</year>;<volume>21</volume>: <fpage>52</fpage>–<lpage>58</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30764-7</pub-id><pub-id pub-id-type="pmid">33058797</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Diekmann</surname><given-names>O</given-names></name>, <name><surname>Heesterbeek</surname><given-names>JAP</given-names></name>, <name><surname>Roberts</surname><given-names>MG</given-names></name>. <article-title>The construction of next-generation matrices for compartmental epidemic models.</article-title><source>J R Soc Interface</source>. <year>2010</year>;<volume>7</volume>: <fpage>873</fpage>–<lpage>885</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1098/rsif.2009.0386</pub-id><pub-id pub-id-type="pmid">19892718</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><collab>CMMID COVID-19 working group</collab>, <name><surname>Davies</surname><given-names>NG</given-names></name>, <name><surname>Klepac</surname><given-names>P</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Prem</surname><given-names>K</given-names></name>, <name><surname>Jit</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Age-dependent effects in the transmission and control of COVID-19 epidemics</article-title>. <source>Nat Med</source>. <year>2020</year>;<volume>26</volume>: <fpage>1205</fpage>–<lpage>1211</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41591-020-0962-9</pub-id><pub-id pub-id-type="pmid">32546824</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Ferretti</surname><given-names>L</given-names></name>, <name><surname>Wymant</surname><given-names>C</given-names></name>, <name><surname>Kendall</surname><given-names>M</given-names></name>, <name><surname>Zhao</surname><given-names>L</given-names></name>, <name><surname>Nurtay</surname><given-names>A</given-names></name>, <name><surname>Abeler-Dörner</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing</article-title>. <source>Science</source>. <year>2020</year>;<volume>368</volume>: eabb6936. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.abb6936</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Prem</surname><given-names>K</given-names></name>, <name><surname>Cook</surname><given-names>AR</given-names></name>, <name><surname>Jit</surname><given-names>M</given-names></name>. <article-title>Projecting social contact matrices in 152 countries using contact surveys and demographic data.</article-title><name><surname>Halloran</surname><given-names>B</given-names></name>, editor. <source>PLoS Comput Biol</source>. <year>2017</year>;<volume>13</volume>: <fpage>e1005697</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pcbi.1005697</pub-id><pub-id pub-id-type="pmid">28898249</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Levin</surname><given-names>AT</given-names></name>, <name><surname>Hanage</surname><given-names>WP</given-names></name>, <name><surname>Owusu-Boaitey</surname><given-names>N</given-names></name>, <name><surname>Cochran</surname><given-names>KB</given-names></name>, <name><surname>Walsh</surname><given-names>SP</given-names></name>, <name><surname>Meyerowitz-Katz</surname><given-names>G</given-names></name>. <article-title>Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications</article-title>. <source>Eur J Epidemiol</source>. <year>2020</year>;<volume>35</volume>: <fpage>1123</fpage>–<lpage>1138</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10654-020-00698-1</pub-id><pub-id pub-id-type="pmid">33289900</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref029">
                <label>29</label>
                <mixed-citation publication-type="other">Ministry of Internal Affairs and Communications. Population Estimates, Monthly Report in September 1, 2020 (Final estimates), February 1, 2021 (Provisional estimates). [cited 3 Mar 2021]. Available: <ext-link xlink:href="https://www.e-stat.go.jp/stat-search/files?page=1&amp;layout=datalist&amp;toukei=00200524&amp;tstat=000000090001&amp;cycle=1&amp;year=20210&amp;month=11010302&amp;tclass1=000001011678&amp;tclass2val=0" ext-link-type="uri">https://www.e-stat.go.jp/stat-search/files?page=1&amp;layout=datalist&amp;toukei=00200524&amp;tstat=000000090001&amp;cycle=1&amp;year=20210&amp;month=11010302&amp;tclass1=000001011678&amp;tclass2val=0</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref030">
                <label>30</label>
                <mixed-citation publication-type="other">Ministry of Health, Labour and Welfare. Open data in “About Coronavirus Disease 2019(COVID-19).” [cited 3 Mar 2021]. Available: <ext-link xlink:href="https://www.mhlw.go.jp/stf/covid-19/open-data.html" ext-link-type="uri">https://www.mhlw.go.jp/stf/covid-19/open-data.html</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref031">
                <label>31</label>
                <mixed-citation publication-type="other">Ministry of Health, Labour and Welfare. Basic Survey on Wage Structure. [cited 3 Mar 2021]. Available: <ext-link xlink:href="https://www.e-stat.go.jp/stat-search/files?page=1&amp;toukei=00450091&amp;tstat=000001011429" ext-link-type="uri">https://www.e-stat.go.jp/stat-search/files?page=1&amp;toukei=00450091&amp;tstat=000001011429</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref032">
                <label>32</label>
                <mixed-citation publication-type="other">Ministry of Health, Labour and Welfare. Survey on Employment Trends. [cited 3 Mar 2021]. Available: <ext-link xlink:href="https://www.e-stat.go.jp/stat-search/files?page=1&amp;toukei=00450073&amp;tstat=000001012468" ext-link-type="uri">https://www.e-stat.go.jp/stat-search/files?page=1&amp;toukei=00450073&amp;tstat=000001012468</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref033">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Polack</surname><given-names>FP</given-names></name>, <name><surname>Thomas</surname><given-names>SJ</given-names></name>, <name><surname>Kitchin</surname><given-names>N</given-names></name>, <name><surname>Absalon</surname><given-names>J</given-names></name>, <name><surname>Gurtman</surname><given-names>A</given-names></name>, <name><surname>Lockhart</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>383</volume>: <fpage>2603</fpage>–<lpage>2615</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Dagan</surname><given-names>N</given-names></name>, <name><surname>Barda</surname><given-names>N</given-names></name>, <name><surname>Kepten</surname><given-names>E</given-names></name>, <name><surname>Miron</surname><given-names>O</given-names></name>, <name><surname>Perchik</surname><given-names>S</given-names></name>, <name><surname>Katz</surname><given-names>MA</given-names></name>, <etal>et al</etal>. <article-title>BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>384</volume>: <fpage>1412</fpage>–<lpage>1423</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2101765</pub-id><pub-id pub-id-type="pmid">33626250</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref035">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Alimohamadi</surname><given-names>Y</given-names></name>, <name><surname>Taghdir</surname><given-names>M</given-names></name>, <name><surname>Sepandi</surname><given-names>M</given-names></name>. <article-title>Estimate of the Basic Reproduction Number for COVID-19: A Systematic Review and Meta-analysis.</article-title><source>J Prev Med Public Health.</source><year>2020</year>;<volume>53</volume>: <fpage>151</fpage>–<lpage>157</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3961/jpmph.20.076</pub-id><pub-id pub-id-type="pmid">32498136</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref036">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>M</given-names></name>, <name><surname>Cook</surname><given-names>AR</given-names></name>, <name><surname>Lim</surname><given-names>JT</given-names></name>, <name><surname>Sun</surname><given-names>Y</given-names></name>, <name><surname>Dickens</surname><given-names>BL</given-names></name>. <article-title>A Systematic Review of COVID-19 Epidemiology Based on Current Evidence.</article-title><source>JCM</source>. <year>2020</year>;<volume>9</volume>: <fpage>967</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/jcm9040967</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref037">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>Kretzschmar</surname><given-names>ME</given-names></name>, <name><surname>Rozhnova</surname><given-names>G</given-names></name>, <name><surname>Bootsma</surname><given-names>MCJ</given-names></name>, <name><surname>van Boven</surname><given-names>M</given-names></name>, <name><surname>van de Wijgert</surname><given-names>JHHM</given-names></name>, <name><surname>Bonten</surname><given-names>MJM</given-names></name>. <article-title>Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study</article-title>. <source>The Lancet Public Health</source>. <year>2020</year>;<volume>5</volume>: <fpage>e452</fpage>–<lpage>e459</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S2468-2667(20)30157-2</pub-id><pub-id pub-id-type="pmid">32682487</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref038">
                <label>38</label>
                <mixed-citation publication-type="journal"><name><surname>Bao</surname><given-names>C</given-names></name>, <name><surname>Pan</surname><given-names>E</given-names></name>, <name><surname>Ai</surname><given-names>J</given-names></name>, <name><surname>Dai</surname><given-names>Q</given-names></name>, <name><surname>Xu</surname><given-names>K</given-names></name>, <name><surname>Shi</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>COVID‐19 outbreak following a single patient exposure at an entertainment site: An epidemiological study.</article-title><source>Transbound Emerg Dis.</source><year>2020</year>; tbed.13742. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/tbed.13742</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref039">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Leung</surname><given-names>K</given-names></name>, <name><surname>Shum</surname><given-names>MH</given-names></name>, <name><surname>Leung</surname><given-names>GM</given-names></name>, <name><surname>Lam</surname><given-names>TT</given-names></name>, <name><surname>Wu</surname><given-names>JT</given-names></name>. <article-title>Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020.</article-title><source>Eurosurveillance.</source><year>2021</year>;<volume>26</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.26.1.2002106</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref040">
                <label>40</label>
                <mixed-citation publication-type="journal"><name><surname>Davies</surname><given-names>NG</given-names></name>, <name><surname>Abbott</surname><given-names>S</given-names></name>, <name><surname>Barnard</surname><given-names>RC</given-names></name>, <name><surname>Jarvis</surname><given-names>CI</given-names></name>, <name><surname>Kucharski</surname><given-names>AJ</given-names></name>, <name><surname>Munday</surname><given-names>JD</given-names></name>, <etal>et al</etal>. <article-title>Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.</article-title><source>Science</source>. <year>2021</year>; <fpage>eabg3055</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.abg3055</pub-id><pub-id pub-id-type="pmid">33658326</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref041">
                <label>41</label>
                <mixed-citation publication-type="journal"><name><surname>Monod</surname><given-names>M</given-names></name>, <name><surname>Blenkinsop</surname><given-names>A</given-names></name>, <name><surname>Xi</surname><given-names>X</given-names></name>, <name><surname>Hebert</surname><given-names>D</given-names></name>, <name><surname>Bershan</surname><given-names>S</given-names></name>, <name><surname>Tietze</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Age groups that sustain resurging COVID-19 epidemics in the United States</article-title>. <source>Science</source>. <year>2021</year>; <fpage>eabe8372</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.abe8372</pub-id><pub-id pub-id-type="pmid">33531384</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref042">
                <label>42</label>
                <mixed-citation publication-type="journal"><name><surname>Doyle</surname><given-names>T</given-names></name>, <name><surname>Kendrick</surname><given-names>K</given-names></name>, <name><surname>Troelstrup</surname><given-names>T</given-names></name>, <name><surname>Gumke</surname><given-names>M</given-names></name>, <name><surname>Edwards</surname><given-names>J</given-names></name>, <name><surname>Chapman</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>COVID-19 in Primary and Secondary School Settings During the First Semester of School Reopening—Florida, August–December 2020.</article-title><source>MMWR Morb Mortal Wkly Rep.</source><year>2021</year>;<volume>70</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.15585/mmwr.mm7012e2</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0257107.ref043">
                <label>43</label>
                <mixed-citation publication-type="book"><name><surname>Alvarez</surname><given-names>FE</given-names></name>, <name><surname>Argente</surname><given-names>D</given-names></name>, <name><surname>Lippi</surname><given-names>F</given-names></name>. <source>A Simple Planning Problem for COVID-19 Lockdown</source>. <publisher-name>National Bureau of Economic Research</publisher-name>; <year>2020</year><month>Apr.</month> Report No.: w26981. <comment>doi: </comment><pub-id pub-id-type="doi">10.3386/w26981</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
          <sub-article article-type="aggregated-review-documents" id="pone.0257107.r001" specific-use="decision-letter">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0257107.r001</article-id>
              <title-group>
                <article-title>Decision Letter 0</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ndeffo Mbah</surname>
                    <given-names>Martial L</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Martial L Ndeffo Mbah</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Martial L Ndeffo Mbah</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0257107" id="rel-obj001" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>0</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">19 May 2021</named-content>
              </p>
              <p>PONE-D-21-12208</p>
              <p>Effective vaccine allocation strategies, balancing economy with infection control against COVID-19 in Japan</p>
              <p>PLOS ONE</p>
              <p>Dear Dr. Kimura,</p>
              <p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
              <p>Please submit your revised manuscript by Jul 03 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
              <p>Please include the following items when submitting your revised manuscript:</p>
              <p>
                <list list-type="bullet">
                  <list-item>
                    <p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p>
                  </list-item>
                  <list-item>
                    <p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p>
                  </list-item>
                  <list-item>
                    <p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p>
                  </list-item>
                </list>
              </p>
              <p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
              <p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link>.</p>
              <p>We look forward to receiving your revised manuscript.</p>
              <p>Kind regards,</p>
              <p>Martial L Ndeffo Mbah, Ph.D</p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
              <p>Journal Requirements:</p>
              <p>When submitting your revision, we need you to address these additional requirements.</p>
              <p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p>
              <p><underline><ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link></underline> and</p>
              <p>
                <ext-link xlink:href="about:blank" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>
              </p>
              <p>2. Thank you for stating the following financial disclosure:</p>
              <p>"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."</p>
              <p>At this time, please address the following queries:</p>
              <p>
                <list list-type="order">
                  <list-item>
                    <p>Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.</p>
                  </list-item>
                  <list-item>
                    <p>State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”</p>
                  </list-item>
                  <list-item>
                    <p>If any authors received a salary from any of your funders, please state which authors and which funders.</p>
                  </list-item>
                  <list-item>
                    <p>If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”</p>
                  </list-item>
                </list>
              </p>
              <p>Please include your amended statements within your cover letter; we will change the online submission form on your behalf.</p>
              <p>[Note: HTML markup is below. Please do not edit.]</p>
              <p>Reviewers' comments:</p>
              <p>Reviewer's Responses to Questions</p>
              <p>
                <bold>Comments to the Author</bold>
              </p>
              <p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
              <p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p>
              <p>Reviewer #1: Partly</p>
              <p>Reviewer #2: Yes</p>
              <p>Reviewer #3: Partly</p>
              <p>**********</p>
              <p>2. Has the statistical analysis been performed appropriately and rigorously? </p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>Reviewer #3: N/A</p>
              <p>**********</p>
              <p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p>
              <p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.</p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>Reviewer #3: Yes</p>
              <p>**********</p>
              <p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
              <p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>Reviewer #3: Yes</p>
              <p>**********</p>
              <p>5. Review Comments to the Author</p>
              <p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p>
              <p>Reviewer #1: The paper is on "Effective vaccine allocation strategies, balancing economy with infection control against COVID-19 in Japan". There were several articles published on that topic this year, and I do not think that this paper enters the top 20%. There is nothing really new here. Here are some comments</p>
              <p>1) (42) "COVID-19 has affected 42 tens of millions of people" it might depend on what "affect" means but if we include lockdowns for instance, it would be more "billions"</p>
              <p>2) (58) the grammar "vaccination in healthcare workers" is odd, but I am not a native English spearker</p>
              <p>3) (88) "lockdown was performed only once" is that a relevent assumption ? so far, many countries have faced second or third wave, so it would make sense to assume that multiple lockdown is possible. Furhermore I have major concern about the design of the lockdown : it is constant, over a given period of time, and uniform over the classes (same theta). Why ? In equation (1) the economic loss is linear... can't we assume that some people can work from home ? can't we assume that E is not linear in theta ? or N ? These assumptions are extremely strong, and not enough discuss. The problem is that all conclusions rely on those assumptions</p>
              <p>4) SEIR model (105) is that relevant for a COVID-19 type of pandemic ? what about asymptomatic ? that was the main challenge at first, and a strong motivation for lockdowns early 2020</p>
              <p>5) (128) again, things are uniform over classes... aren't there are more interactions within age classes ? Here having a similar theta is weird</p>
              <p>Reviewer #2: Reviewer Report</p>
              <p>(Recommendation)</p>
              <p>I recommend the research article. However, it would be appropriate for the authors to consider some recommendations.</p>
              <p>1. Summary of the investigation:</p>
              <p>The article uses the SEIR model. Apply an optimization method with the differential evolution method and use a proven Python algorithm. The research question: What is the most appropriate vaccination strategy based on economic cost? and of course, it assumes other variables or parameters that the literature and evidence review suggests. In this context, it seeks to balance the economy and infection control in Japan.</p>
              <p>One of the greatest strengths is in having a proven methodology that is better than other existing ones. But as a weakness is that no appendix shows how the theoretical-mathematical model derives, and secondly, to be able to replicate the results in Python. Of course, this situation does not affect the results.</p>
              <p>The main result of the study is that the effective vaccination strategy that prioritizes the younger generation outperformed the other strategies in terms of deaths, explained by the contact rate and therefore the transmission.</p>
              <p>2. Evidence and examples:</p>
              <p>First, a review of the literature on the current situation of the Vaccine against the Pandemic would be important. It could expand the description of the state of the art of public health policies that have been carried out and compare not only at the level of Japan but at least at the Asian or the Asia Pacific and/or Global level.</p>
              <p>Second, review of the empirical evidence that can be presented (Results) and compared (Discussion) in the present study. It is important to compare the results with others in the region, at the level of Asia, Asia-Pacific, at the level of developed countries or the world.</p>
              <p>Reviewer #3: Please see an attachment file.</p>
              <p>Please see an attachment file.</p>
              <p>Please see an attachment file.</p>
              <p>Please see an attachment file.</p>
              <p>Please see an attachment file.</p>
              <p>Please see an attachment file.</p>
              <p>Please see an attachment file.</p>
              <p>**********</p>
              <p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
              <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
              <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p>
              <p>Reviewer #1: No</p>
              <p>Reviewer #2: No</p>
              <p>Reviewer #3: <bold>Yes: </bold>Tsuyoshi HONDOU</p>
              <p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
              <p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
              <supplementary-material id="pone.0257107.s008" position="float" content-type="local-data">
                <label>Attachment</label>
                <caption>
                  <p>Submitted filename: <named-content content-type="submitted-filename">Reviewer Report - recommendation.docx</named-content></p>
                </caption>
                <media xlink:href="pone.0257107.s008.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pone.0257107.s009" position="float" content-type="local-data">
                <label>Attachment</label>
                <caption>
                  <p>Submitted filename: <named-content content-type="submitted-filename">Reviewers report (PLOS).pdf</named-content></p>
                </caption>
                <media xlink:href="pone.0257107.s009.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </body>
          </sub-article>
          <sub-article article-type="author-comment" id="pone.0257107.r002">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0257107.r002</article-id>
              <title-group>
                <article-title>Author response to Decision Letter 0</article-title>
              </title-group>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0257107" id="rel-obj002" related-article-type="editor-report"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="author-response-date">6 Aug 2021</named-content>
              </p>
              <p>We are most grateful to you and the reviewers for the comments on our manuscript.</p>
              <p>See the file uploaded to response to reviewers.</p>
              <supplementary-material id="pone.0257107.s010" position="float" content-type="local-data">
                <label>Attachment</label>
                <caption>
                  <p>Submitted filename: <named-content content-type="submitted-filename">review_R1_26July2021.docx</named-content></p>
                </caption>
                <media xlink:href="pone.0257107.s010.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </body>
          </sub-article>
          <sub-article article-type="aggregated-review-documents" id="pone.0257107.r003" specific-use="decision-letter">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0257107.r003</article-id>
              <title-group>
                <article-title>Decision Letter 1</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ndeffo Mbah</surname>
                    <given-names>Martial L</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Martial L Ndeffo Mbah</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Martial L Ndeffo Mbah</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0257107" id="rel-obj003" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">24 Aug 2021</named-content>
              </p>
              <p>Effective vaccine allocation strategies, balancing economy with infection control against COVID-19 in Japan</p>
              <p>PONE-D-21-12208R1</p>
              <p>Dear Dr. Kimura,</p>
              <p>We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p>
              <p>Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p>
              <p>An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <ext-link xlink:href="http://www.editorialmanager.com/pone/" ext-link-type="uri">http://www.editorialmanager.com/pone/</ext-link>, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <email>authorbilling@plos.org</email>.</p>
              <p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p>
              <p>Kind regards,</p>
              <p>Martial L Ndeffo Mbah, Ph.D</p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
              <p>Additional Editor Comments (optional):</p>
              <p>Reviewers' comments:</p>
              <p>Reviewer's Responses to Questions</p>
              <p>
                <bold>Comments to the Author</bold>
              </p>
              <p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.</p>
              <p>Reviewer #1: All comments have been addressed</p>
              <p>Reviewer #2: All comments have been addressed</p>
              <p>**********</p>
              <p>2. Is the manuscript technically sound, and do the data support the conclusions?</p>
              <p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>3. Has the statistical analysis been performed appropriately and rigorously? </p>
              <p>Reviewer #1: N/A</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>4. Have the authors made all data underlying the findings in their manuscript fully available?</p>
              <p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.</p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>5. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
              <p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>6. Review Comments to the Author</p>
              <p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p>
              <p>Reviewer #1: The paper has been substentialy improved. I still do no see real innovations in the paper (compared with several papers published recently on the same topic), but since the editor and the two other referees think that it is relevant that such a paper could be published in PLOS ONE, I will not go against it</p>
              <p>Reviewer #2: The authors respond appropriately to the reviewers' suggestions.</p>
              <p>The authors use and extend the SEIR model. They apply an optimization method with the differential evolution method and use a Python algorithm.</p>
              <p>The authors manage to add the observations by making an article more suitable for publication according to the journal Plos-One.</p>
              <p>**********</p>
              <p>7. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
              <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
              <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p>
              <p>Reviewer #1: No</p>
              <p>Reviewer #2: No</p>
            </body>
          </sub-article>
          <sub-article article-type="editor-report" id="pone.0257107.r004" specific-use="acceptance-letter">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0257107.r004</article-id>
              <title-group>
                <article-title>Acceptance letter</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ndeffo Mbah</surname>
                    <given-names>Martial L</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Martial L Ndeffo Mbah</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Martial L Ndeffo Mbah</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0257107" id="rel-obj004" related-article-type="reviewed-article"/>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">26 Aug 2021</named-content>
              </p>
              <p>PONE-D-21-12208R1 </p>
              <p>Effective vaccine allocation strategies, balancing economy with infection control against COVID-19 in Japan </p>
              <p>Dear Dr. Kimura:</p>
              <p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p>
              <p>If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email>onepress@plos.org</email>.</p>
              <p>If we can help with anything else, please email us at <email>plosone@plos.org</email>. </p>
              <p>Thank you for submitting your work to PLOS ONE and supporting open access. </p>
              <p>Kind regards, </p>
              <p>PLOS ONE Editorial Office Staff</p>
              <p>on behalf of</p>
              <p>Dr. Martial L Ndeffo Mbah </p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
            </body>
          </sub-article>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
